At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow. At this year's meeting of the European Society of Retina Specialists ...

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery. The European Society of Retina ...

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...

The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress. Marion Munk, a medical retina and uveitis specialist from Switzerland, introduced the ...

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD, and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed ...

María Berrocal, from Drs. Berrocal and Associates in San Juan, Puerto Rico, delivered the Ingrid Kreissig Award Lecture titled "Throwing away wisdom: How we abandon what works." Her presentation ...

The Vit-Buckle Symposium will be a part of the at EURETINA annual meeting in Paris, France again this year. To discuss this symposium, Aleksandra Rachitskaya, MD, FASRS, from Cleveland Clinic Cole Eye ...

Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies. Note: The following transcript has been lightly edited for clarity. Sofia Androudi, MD: ...

At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma. Jean-Francois Korobelnik, MD, ...

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes. Now is an exciting time to be a ...